RNA therapies startup Ochre Bio lands $30M to take on chronic liver disease

Ochre Bio’s Series A financing will support development of RNA therapies for chronic liver disease. Longer term, the company aims to develop therapies that regenerate organs in patients, potentially avoiding the need for organ transplants.

Leave a Comment

Your email address will not be published.

Generated by Feedzy